larotinib (Z650) / HEC Pharm 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Trial completion date, Trial primary completion date:  Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function (clinicaltrials.gov) -  Mar 21, 2023   
    P1,  N=32, Not yet recruiting, 
    Initiation date: Dec 2023 --> May 2024 Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Dec 2024
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Trial completion:  ADME Study of [14C]- Larotinib in Healthy Male Subjects (clinicaltrials.gov) -  Mar 21, 2023   
    P1,  N=6, Completed, 
    Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Dec 2024 Active, not recruiting --> Completed
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Trial completion date, Trial primary completion date, Metastases:  Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer (clinicaltrials.gov) -  Aug 15, 2022   
    P3,  N=416, Recruiting, 
    Trial completion date: Oct 2022 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Jan 2023 Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer (clinicaltrials.gov) -  May 6, 2022   
    P1,  N=13, Terminated, 
    Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Aug 2023 N=45 --> 13 | Trial completion date: Mar 2022 --> Sep 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2021; Combined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects.
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification (clinicaltrials.gov) -  May 6, 2022   
    P1/2,  N=45, Recruiting, 
    N=45 --> 13 | Trial completion date: Mar 2022 --> Sep 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2021; Combined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects. Active, not recruiting --> Recruiting | Trial completion date: Jun 2021 --> Apr 2023 | Trial primary completion date: Apr 2021 --> Dec 2022
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Trial initiation date:  Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function (clinicaltrials.gov) -  May 6, 2022   
    P1,  N=32, Not yet recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Jun 2021 --> Apr 2023 | Trial primary completion date: Apr 2021 --> Dec 2022 Initiation date: Nov 2021 --> Nov 2022
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Enrollment closed, Trial primary completion date:  ADME Study of [14C]- Larotinib in Healthy Male Subjects (clinicaltrials.gov) -  Mar 10, 2022   
    P1,  N=6, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Mar 2022 --> Aug 2022 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Jan 2022
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Trial completion date, Trial primary completion date, Metastases:  Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification (clinicaltrials.gov) -  Mar 18, 2021   
    P1/2,  N=45, Active, not recruiting, 
    Rhamnolipid's ability to generate reactive oxygen species has thrown light on the mechanism through which the killing of test bacteria may occur. Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2020 --> Apr 2021
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer (clinicaltrials.gov) -  Mar 18, 2021   
    P3,  N=416, Recruiting, 
    Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2020 --> Apr 2021 Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Nov 2022 | Initiation date: Oct 2020 --> Jan 2021 | Trial primary completion date: Jul 2021 --> Aug 2022
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Trial completion date, Trial primary completion date, Metastases:  Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification (clinicaltrials.gov) -  Oct 21, 2020   
    P1/2,  N=45, Active, not recruiting, 
    Continuous oral administration of larotinib mesylate at 50-400 mg daily demonstrated a favorable safety profile, and anti-tumor activity was observed in patients with advanced solid tumors. Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: May 2020 --> Dec 2020
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Trial initiation date, Metastases:  Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer (clinicaltrials.gov) -  Sep 13, 2020   
    P3,  N=416, Not yet recruiting, 
    Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: May 2020 --> Dec 2020 Initiation date: Jul 2020 --> Oct 2020
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification (clinicaltrials.gov) -  Mar 24, 2020   
    P1/2,  N=45, Active, not recruiting, 
    Initiation date: Jul 2020 --> Oct 2020 Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> May 2020 | Trial primary completion date: Oct 2019 --> May 2020
  • ||||||||||  larotinib (Z650) / HEC Pharm
    Enrollment open, Metastases:  Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer (clinicaltrials.gov) -  Feb 10, 2020   
    P1,  N=45, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> May 2020 | Trial primary completion date: Oct 2019 --> May 2020 Not yet recruiting --> Recruiting